Autonomix Medical (NASDAQ:AMIX) vs. Atossa Genetics (NASDAQ:ATOS) Head-To-Head Survey

Atossa Genetics (NASDAQ:ATOS) and Autonomix Medical (NASDAQ:AMIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Atossa Genetics and Autonomix Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2	0	2	1	2.40
Autonomix Medical	1	1	1	0	2.00

Atossa Genetics presently has a consensus price target of $6.25, suggesting a potential upside of 722.91%. Autonomix Medical has a consensus price target of $5.00, suggesting a potential upside of 474.71%. Given Atossa Genetics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Atossa Genetics is more favorable than Autonomix Medical.

Volatility & Risk

Atossa Genetics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Autonomix Medical has a beta of -2.87, meaning that its stock price is 387% less volatile than the S&P 500.

Institutional & Insider Ownership

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are held by institutional investors. 8.7% of Atossa Genetics shares are held by company insiders. Comparatively, 6.2% of Autonomix Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Atossa Genetics and Autonomix Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-49.42%	-44.76%
Autonomix Medical	N/A	-213.42%	-172.57%

Earnings & Valuation

This table compares Atossa Genetics and Autonomix Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$25.50 million	($0.24)	-3.16
Autonomix Medical	N/A	N/A	-$11.41 million	($4.65)	-0.19

Atossa Genetics is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Atossa Genetics beats Autonomix Medical on 10 of the 12 factors compared between the two stocks.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.